With the headquarter located in San Antonio, South Texas Accelerated Research Therapeutics (START) conducts the world’s largest Phase I medical oncology program – putting more than 650 patients per year on Phase I trials. START has opened its second collaboration at Madrid (Spain) in 2008.
In 2011, START opened its third collaboration, which is the first in Asia, at Shanghai, China. START Shanghai is dedicated to the conduct of early Phase I Clinical Trials of novel anticancer agents. By accelerating the development of new agents, START Shanghai aims to improve patients’ survival and life quality in China.
START Shanghai has high quality operational facilitates located at the Fudan University Shanghai Cancer Center (FUSCC). Strong partnership with the FUSCC has also enhanced START Shanghai with highly trained and extensively experienced operational team members. As part of fully integrated START Network of clinical sites, START Shanghai operates clinical trials under uniformed standard operating procedures (SOP) which fulfill the requirements of ICH and Chinese GCPs. Moreover, START Shanghai’s unique Electronic Medical Record (EMR) technology can benefit sponsors with easy clinical trial data monitoring and management.
START Shanghai offers high quality early phase clinical trial services to the collaborations among Pharma/Bio companies, clinical physicians and cancer patients in China. The vision of START Shanghai is to be the first and most respected early-phase oncology clinical partner in China.
'Our sole mission is to accelerate the development of new therapies for the treatment and eventual cure of cancer by taking the skills and expertise that has been created here and expanding it to the rest of the world.'